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earzt@fbmc.fcen.uba.arAbstractInflammatory responses are elicited after injury, involving release of inflammatory mediators
that ultimately lead, at the molecular level, to the activation of specific transcription factors
(TFs; mainly activator protein 1 and nuclear factor-kB). These TFs propagate inflammation by
inducing the expression of cytokines and chemokines. The neuroendocrine system has a
determinant role in the maintenance of homeostasis, to avoid exacerbated inflammatory
responses. Glucocorticoids (GCs) are the key neuroendocrine regulators of the inflammatory
response. In this study, we describe the molecular mechanisms involved in the interplay
between inflammatory cytokines, the neuroendocrine axis and GCs necessary for the control
of inflammation. Targeting and modulation of the glucocorticoid receptor (GR) and its
activity is a common therapeutic strategy to reduce pathological signaling. Poly (ADP-ribose)
polymerase 1 (PARP1) is an enzyme that catalyzes the addition of PAR on target proteins,
a post-translational modification termed PARylation. PARP1 has a central role in
transcriptional regulation of inflammatory mediators, both in neuroendocrine tumors and
in CNS cells. It is also involved in modulation of several nuclear receptors. Therefore, PARP1
and GR share common inflammatory pathways with antagonic roles in the control of
inflammatory processes, which are crucial for the effective maintenance of homeostasis.Key Words
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.0 UEndocrine Connections
(2014) 3, R1–R12IntroductionThe inflammatory response is a physiological process that
protects the organism against infection and pathogens
and repairs tissue damaged by injuries. It is normally
beneficial to the organism, provoking the activation of
various proinflammatory mediators in order to remove
the damaging agent and restoring tissue function
and structure (1). Biologically, inflammation advancesthrough several stages. At the cellular level there is
a marked response to proinflammatory stimuli, and as
a result cytokine and chemokine cascades are initiated (2).
The increase in these inflammatory mediators – cytokines,
chemokines, growth factors, receptors, enzymes,
and adhesion molecules – is considered pivotal for
the progression and propagation of inflammation.sed under a Creative Commons
nported License.
E
n
d
o
cr
in
e
C
o
n
n
e
ct
io
n
s
Review F Aprile-Garcia et al. Neuroendocrine control of
inflammation
2–12 3 :R2On a molecular level, the appearance of proinflammatory
signals culminates predominantly in the activation of
activator protein 1 (AP1) and nuclear factor-kB (NF-kB). In
turn, both transcription factors (TFs) induce the expression
of the aforementioned inflammatory mediators, thus
propagating cellular inflammation (3, 4, 5).
However, return to homeostasis – in which the
neuroendocrine system has a paramount role – is necessary,
considering that if the inflammatory process itself is
prolonged it can lead to tissue injury and states of chronic
inflammation and autoimmunity (6). This dysregulation
has been identified as one of the major pathophysiological
mechanisms underlying life-threatening human diseases
(6, 7). Because of this determinant role in disease and also
because inflammation is activated not only by infectious
but also by environmental, behavioral, and psychological
stimuli, inflammation is emerging as a main player
controlling the balance between stress experience and
human health (8). Indeed, there are mechanisms for the
appropriate termination of the inflammatory response,
and deficiencies in these mechanisms contribute to the
appearance of inflammatory diseases.
After an injury, an important feature of the inflam-
matory response is the local release of a number of
inflammatory mediators such as cytokines (interleukin 1
(IL1), IL6, and tumor necrosis factor a (TNFa)), which then
act in the CNS activating the hypothalamic–pituitary–
adrenal (HPA) axis, the main component of the endocrine
stress response. IL1 and other cytokines act on the brain
via several communication pathways: i) primary afferent
neurons that innervate the periphery; ii) a humoral
pathway that involves production of proinflammatory
cytokines by macrophage-like cells and posterior diffusion
across the blood–brain–barrier; and iii) cytokine receptors
on endothelial cells of brain venules which mediate local
production of prostaglandins (9, 10). This results in a
neuroendocrine cascade of hormone signals that begins in
the brain and ends with glucocorticoid (GC) secretion
(cortisol in humans and corticosterone in rats, mice, and
other species). When stimulated, neurons in the para-
ventricular nucleus of the hypothalamus release cortico-
tropin-releasing hormone and arginine vasopressin. These
factors cause secretion of adrenocorticotropic hormone in
the anterior pituitary, which is released into the systemic
circulation causing synthesis and secretion of GCs by the
adrenal cortex (11, 12). The inflammatory response is
mainly terminated by GCs, the end product of HPA axis
activation, by a well-defined mechanism we describe
below (13, 14, 15, 16, 17).http://www.endocrineconnections.org
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GCs are key neuroendocrine regulators of the inflam-
matory response. In a neuroendocrine-inflammatory feed-
back pathway, activation of the HPA axis leads to a rise in
systemic GC levels which feedback and control the
inflammatory response. Through this loop, GCs have an
active participation in the interaction between the cellular
components of the immune system and the neuroendo-
crine system, thus assuring maintenance of homeostasis
avoiding excessive inflammatory effects that could be
deleterious (10, 18). GCs are vital hormones that regulate a
wide array of functions. Among others, they regulate
metabolism, the immune response, neuronal survival, and
neurogenesis, so also regulating behavioral function
(11, 19). Thus, GCs are released in response to physical,
emotional, and/or metabolic stress, and their effects serve
as adaptive responses to stressful circumstances.
GCs belong to the steroid hormone family, a group of
small lipophilic compounds derived from cholesterol, its
common precursor. Steroid hormones are generally
grouped according to the receptors they bind and their
biological activity: progestins, androgens, estrogens, and
corticoids. In turn, corticoids can be divided in miner-
alocorticoids, which regulate ion transport, and GCs,
which have a wide variety of activities, including
resistance to stress and immunosuppressive and anti-
inflammatory actions (11, 19). Owing to their lipophilic
nature, steroid hormones can freely diffuse through the
cell membrane and bind to their cytoplasmic receptors. At
the cellular level, the action of GCs is first regulated by
activity of the enzyme 11b-hydroxysteroid dehydrogenase
type 1 (11b-HSD1), which interconverts inactive GCs to
their active counterparts, thus determining activation of
GC before receptor binding. It has been reported that
TNFa and IL1b increase the expression and activity of
11b-HSD1 in mesenchymal stromal cells, and combined
treatment with GCs enhances this effect synergically
(20, 21, 22). This further stimulation of 11b-HSD1
expression by GCs may be a mechanism to selectively
increase local GC action during inflammation (23, 24).
GCs exert their biological effects binding to the gluco-
corticoid receptor (GR), which is a ligand-activated TF that
regulates the expression of target genes, either positively
or negatively (18, 25). In an uninduced state, the GR
resides predominantly in the cell cytoplasm in an
inactivated form as part of a multimeric chaperone
complex, consisting of several heat shock proteins and
immunophilins. This complex keeps the ligand-binding
pocket of the GR receptive to hormone binding andThis work is licensed under a Creative Commons
Attribution 3.0 Unported License.
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3–12 3 :R3inactivates the nuclear localization signal (NLS). Once GCs
bind to the GR, there is a conformational change in the
receptor that allows the GR to dissociate from some
components of the chaperone complex and expose the
NLS, so the GR is able to move freely and translocate into
the nucleus (26, 27). Consequently, ligand-bound GR
gives rise to positive or negative transcriptional effects.Transcriptional regulation
Promoter activation of GR transcriptional targets can be
elicited by different mechanisms: binding of dimeric,
activating GR into GC response elements (GRE); DNA
binding of the GR in a concerted manner with TFs; or
binding of the GR to a TF by means of a tethering
mechanism. The transactivation results in the expression
of a number of anti-inflammatory proteins such as NF-kB
inhibitor a (IkBa), GC-induced leucine zipper (GILZ), and
dual-specificity phosphatase (DUSP) and IL10 (4, 28).
However, the anti-inflammatory effects of GCs are mostly
mediated via the interference elicited by a monomeric GR
with the transactivation capacity of TFs, such as NF-kB and
AP1, via a tethering mechanism named transrepression
(18, 29, 30, 31). Also, GR can negatively regulate
transcription by competing for an overlapping binding
site (competitive GRE) or via DNA-binding with another
TF (composite GRE), or else sequestering a DNA-bound TF
(25). Thus, several TFs – NF-kB, AP1, Sp1, STAT3 among
others – can work in concert with the GR regulating the
fine-tuning of transcription, either in a positive or
negative manner (32). The most prominent anti-
inflammatory effects of GCs are elicited mainly by
inhibiting the activity of TFs such as AP1 and NF-kB,
which are involved in the activation of proinflammatory
and immunoregulatory genes such as inflammatory
cytokines (e.g. IL1b, IL6, and TNFa), cytokine receptors,
adhesion molecules (e.g. ICAM1, VCAM, and E-selectin),
and chemotactic proteins and thus are indispensable for
the propagation of inflammation (29, 33). All of these
genes have one or more NF-kB and/or AP1-responsive
elements in their promoters (18, 29, 34). Indeed, the first
described anti-inflammatory activity of GCs involving
transrepression was the physical interaction between GR
and AP1 (35), which results in the inhibition of inflam-
matory cytokine IL2 expression (36). NF-kB regulates a
wide array of inflammatory cytokines, such as TNFa and
IL1b. Thus, inhibition of NF-kB activity mediated by GCs
is a main feature of the GR-elicited anti-inflammatory
action (4, 31, 37). It also inhibits NFAT-dependent IL2
transcription, by a mechanism involving the cooperativehttp://www.endocrineconnections.org
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Published by Bioscientifica Ltdbinding between NFAT and AP1 dimers by protein–protein
interaction (38). The main mechanism of the GR action
over these TFs is via the transrepression mechanism: the
activated GR tethers to the TF, modulating transrepression
of the targeted genes, thereby inhibiting gene expression.
The GR does not inhibit the binding of NF-kB or AP1 to
their responsive elements in the gene promoter. Instead,
GR binds proximal to the NF-kB or AP1-binding site and
interacts with these TFs: for example, interaction of the GR
with the C-terminal activation domains of NF-kB p65 is
determinant for its repressive effect on NF-kB-regulated
gene expression (39). The cross-talk mechanism is not
restricted to these well known TFs, but has been expanded
in the past years to other factors including CREB, NFAT,
STAT, T-bet, and GATA-3 (40, 41, 42).GCs anti-inflammatory effects and
therapeutic applications
The interplay mentioned between cytokines, HPA axis
activation and GCs modulation has an important role in
the control of inflammation, given the fact that the
increase in GCs levels elicited after HPA-axis activation
by proinflammatory cytokines contributes to maintain
homeostasis during immune response (43). A situation
of an excessive tissue inflammation plays a critical role
in the development of chronic inflammatory disorders.
The administration of GC analogs is often employed in the
clinic in situations of unresolved inflammatory processes,
representing the first line of drugs used to help control the
homeostasis of organism in allergic, inflammatory, and
autoimmune disorders (44, 45, 46). It is generally accepted
that the transrepression mechanisms mediated by the GR
sustain the beneficial anti-inflammatory action of GCs,
whereas their side effects are due to direct binding of GR
to responsive promoter elements as depicted before. Along
with this notion, the ideal GC analogs for therapeutic
purposes should be those that have only high transrepres-
sion but very low residual transactivation properties,
therefore, causing minimal side effects. Several steroidal
and nonsteroidal ligands of GR have been reported to have
this dissociated function between transactivation and
transrepressive mechanisms (44, 45, 46, 47). Thus, these
compounds repress activity of not only NF-kB and AP1 but
also other TFs, showing anti-inflammatory and immuno-
supressive activities in vivo (48, 49, 50, 51). However, GCs
can induce gene transcription not only by binding GRE
elements but also in combination with other TFs and via
promoter elements that do not involve GR dimerization
or DNA interaction; therefore, unexpected secondary sideThis work is licensed under a Creative Commons
Attribution 3.0 Unported License.
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4–12 3 :R4effects might appear (52). Consequently, the future search
for GR ligands should balance between undesirable
transactivation and efficient transrepressive properties
in vivo (44, 46). Considering the high percentage of GCs
resistance seen daily in the clinical practice, it would be
important to know whether these selective GR modulators
are more efficient than traditional GCs to overcome
resistance minimizing side effects (53).Hormone receptor modulation for the
control of inflammation
Members of the family of steroid hormones, as is the case
for GCs, have a big influence on a wide variety of
physiological responses, leading to homeostasis, including
maintenance of neuroendocrine circuits, both in health
and disease. These effects are mediated by specific receptor
activation. Steroid receptors are members of the nuclear
receptor (NR) superfamily. They can be grouped into four
classes according to their ligand-binding, DNA-binding,
and dimerization properties: steroid receptors –
progesterone receptor (PR), androgen receptor (AR),
estrogen receptor (ER), mineralocorticoid receptor, and
GR – RXR heterodimers – including retinoic acid receptor
(RAR) and thyroid hormone receptor – and orphan
receptors (54). As previously detailed for the GR, the
other members of the NR superfamily also contribute both
positively and negatively to gene expression after a
stimulus, as well as interacting and interfering with
other signaling pathways (e.g. inhibition of gene acti-
vation by NF-kB or AP1), thus representing an important
regulatory link between the endocrine and immune
system (34). Dysregulation of these processes can lead to
disease. As such, dysregulation of GR, as well as other NRs,
have consequences in the control of inflammation. The
functional interaction between NRs and NF-kB has been
proposed to play a role in tumorigenesis in vivo (55, 56).
Over the past few years, an increasing body of evidence
reveals that NF-kB plays a critical role in tumor develop-
ment. The potential of NRs to modulate the activity of this
widespread TF has been reported and their therapeutic
potential has been illustrated (34, 57).
Treatments targeting each hormone receptor are
generally employed to reduce pathological signaling
through these receptors thereby to inhibit malignant cell
proliferation. Although these treatments are effective
for many patients, resistance is also a common feature of
these therapies (58). Thus, new treatment strategies are
needed in these cases. Specific intracellular modulation of
receptor activity may be one feasible alternative. In thishttp://www.endocrineconnections.org
DOI: 10.1530/EC-13-0079
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Published by Bioscientifica Ltdregard, NRs are known to be modulated by different
mechanisms and molecules, involving regulation of its
expression, post-translational modifications, and activity
modulation by coregulators (34, 59, 60, 61, 62).
In this matter, one specific molecule that has caught
the attention of researchers in the last few years is poly
(ADP-ribose) polymerase 1 (PARP1). This long-known
protein is starting to reveal new and exciting functions,
some of them related with endocrine pathologies, by
means of interaction and modulation of NRs activity.PARP: introduction and transcriptional
regulation
PARP conform a family of 18 proteins that were identified
by homology searching and characterization in silico
(63, 64). Members of this family share a highly conserved
PARP signature motif in the catalytic domain. These
enzymes catalyze the addition of PAR on target proteins.
PAR is a large and negatively charged polymer that works as
a post-translational modification. The cellular content of
PAR is produced by PARP’s catalytic activity, which
polymerizes ADP-ribose units from donor NADCmolecules
on target proteins (65, 66). This modification most likely
occurs on glutamate, aspartate, and lysine residues. There
has been some progress on elucidating the specific sites of
PAR addition (67). The covalent PAR attachment alters the
activity of the modified proteins by means of charge and
steric effects, thus altering protein–protein interactions,
nucleic acid–protein interactions, enzymatic activity, and
subcellular localization (68). The most studied member of
the family is PARP1, a nuclear enzyme with a wide variety of
functions. It was originally described as capable of binding
to damaged DNA and thus become activated, and was
therefore described as an important mediator of the
responses to DNA damage (69). Over the last decade, it
has been shown that PARP1 not only mediates DNA repair,
but it also has important roles in different nuclear
processes such as replication, chromatin remodeling,
transcription, and maintenance of genomic stability (70).
The number of proteins known to be targets of PARP1
enzymatic activity is on permanent growth. It has been
shown that PARP1 modifies histones, TFs, nuclear enzymes,
and nuclear structural proteins. PARP1 parylates histones,
thereby regulating chromatin structure (71). It also
parylates a number of DNA repair proteins such as p53
(72). PARP1 has also been reported to parylate and alter
the function of numerous TFs, including AP1, NF-kB,
CTCF, and YY1 (73). Thus, the cellular functions of
PARP1 are ultimately defined by protein parylation.This work is licensed under a Creative Commons
Attribution 3.0 Unported License.
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5–12 3 :R5However, functions of PARP1 are not only mediated by
its intrinsic activity of parylation but also due to association
with different proteins, such as transcription-related factors
(73). In particular, the role of PARP1 in gene regulation
has received considerable attention (73, 74, 75), and it
has been established that it can modulate gene expression
under basal, signal-activated, and stress-activated
conditions at different levels: i) modulating chromatin
structure, ii) serving as a coregulator with DNA-binding TFs,
and iii) modulating DNA methylation (70).Modulation of chromatin
The first reported effects of PARP1 on the genome were
chromatin structure modulation and parylation of
histones (76, 77) and were afterwards validated (78, 79).
PARP1 binds to nucleosomes and interacts dynamically
with different types of chromatin domains, thereby
modulating chromatin structure (71). Activation of
PARP1 promotes chromatin decondenzation and restor-
ation of transcription (78). PARP1 localizes to the
promoters of almost all actively transcribed genes (80),
suggesting a role in promoting the formation of chromatin
structures that are permissive to transcription (78, 80, 81).Transcriptional coregulation
Regulation of gene expression by PARP1 may also be
accomplished by serving as a coregulator, acting together
with the transcription machinery, other coregulators with
enzymatic activities, and with sequence-specific DNA-
binding TFs, such as NF-kB, Elk1, NFAT, Oct1, and Sox2.
Interestingly, PARP1 can interact with NRs such as ER, PR,
and RAR (65, 71, 73). The effect of PARP1 over these
activators may be stimulatory or inhibitory and may
require or not its enzymatic activity. PARP1 is enriched
around the transcription start sites of the genes that are
actively expressed, therefore is an excellent marker of
active promoters. Remarkably, PARP1 was previously
identified as the basal TFIIC (82) that coregulates RNA
polymerase II preinitiation complex formation before
TFIID binding, therefore enhancing gene transcription.
Also, several reports have shown that PARP1 is responsible
for assembling coregulator complexes at the promoter of
target genes, functioning as a scaffold protein, without
binding to DNA or requiring its catalytic activity,
promoting the recruitment of other coregulatory enzymes
required for transcription (70). For example, in response to
proinflammatory stimuli, PARP1 facilitates direct physical
interaction and functional cooperation between thehttp://www.endocrineconnections.org
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Published by Bioscientifica Ltdacetyltransferase p300/CBP, the p50 subunit of NF-kB
and the mediator complex (83, 84). In other cases, PARP1
has been described as a promoter-specific ‘exchange
factor’, releasing inhibitory factors and recruiting stimu-
latory factors to TFs bound to these promoters (81, 85).Modulation of DNA methylation
It has been shown that PARP1 can affect the methylation
of genomic DNA (86, 87). PARP1 regulates both the
expression and activity of the DNA methyltransferase,
Dnmt1 (88), and it was also described to directly interact
with Dnmt1 after attachment of new PAR polymers,
inhibiting Dnmt1 DNA methyltransferase activity (89).PARP1 and neuroendocrine mediators
PARP1 has been linked with the regulation of the activity
of several NRs, specially in the modulation of endocrine
processes. Particularly, it has been shown that PARP1 is
involved in several NRs-mediated transcription (Fig. 1).
PARP1 acts as a coregulator in the concert of a wide variety
of transcriptional regulators that give temporal and spatial
specificity to gene expression.
PARP1 has been described to be recruited to chromatin
areas surrounding the estrogen response element present
in the pS2 promoter in 17b-estradiol (E2)-treated MCF7
cells as part of a specific coactivator complex recruited to
the liganded ERa (81). In this regard, a rapid increase in
PARP1 recruitment together with coactivators and Pol2
and the elimination of corepressors in response to E2 was
reported, events that were necessary for transcriptional
activation. Furthermore, pharmacological or genetic
inhibition of PARP1 blocked ERa-dependent gene
expression (81).
Another study (85) focused on PARP1 effects over RAR-
dependent transcription. This study demonstrated a
functional and physical interaction between PARP1 and
RAR leading to RAR-mediated transcriptional activation,
thus concluding that PARP1 is an essential coregulator for
RA-induced gene expression in vivo. More specifically,
PARP1 is a cofactor that makes the switch from inactive to
active RAR-dependent promoters. This switch is determi-
nant for the transcriptional status and constitutes an
additional mechanism for gene regulation.
PARP1 coregulation of NRs activity has been shown to
have a role on cancer growth and progression of endocrine
tumors. In this line, PARP1 is involved in prostate and
breast cancer, by means of modulating AR and PR
respectively. In a recent report (90), it was shown thatThis work is licensed under a Creative Commons
Attribution 3.0 Unported License.
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Figure 1
PARP1 regulation of nuclear receptors (NRs) in endocrine tissues. PARP1
regulates NRs transcriptional activity through different mechanisms
depending on cell context. PARP1 induces the transcriptional activity of
ligand-activated ER in the breast cancer cells by recluting transcriptional
coactivators to ER target genes. PARP1 modulates AR–chromatin
interaction in prostate cancer cells, thereby increasing AR-mediated
transcription, in a parylation-independent manner. PARP1 induces
ligand-activated PR-mediated transcription in breast cancer cells in a
parylation-dependent manner. The effect of PARP1 on GR-mediated
transcription in the neuroendocrine system has yet to be addressed.
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6–12 3 :R6PARP1 has protumorigenic effects on positive-AR prostate
cancer cells. PARP1 seems to be recruited to AR-dependent
promoters, where it promotes AR occupancy and tran-
scriptional function, by modulating AR–chromatin
interaction. PARP1 inhibition reduced prostate-specific
AR target genes. It is important to note that PARP1
regulation of AR activity is not attributable to parylation.
There also seems to be a correlation between prostate
cancer progression and PARP1 enzymatic activity, because
this activity is enhanced on advanced prostate cancers.
Furthermore, PARP1 activity is required for tumor cell
growth in vivo and its targeting potently suppresses tumor
cell proliferation, suggesting that PARP1 can be targeted
on human prostate cancer to suppress tumor growth (90).http://www.endocrineconnections.org
DOI: 10.1530/EC-13-0079
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Published by Bioscientifica LtdPARP1 also has a role in breast cancer, mediated by its
interaction with the PR. It was first discovered that PARP1
was part of a protein complex that could interact in vitro
with ligand-activated PR and assist on DNA binding (91).
When the effects of PARP1 over the PR were evaluated in
breast cancer cells treated with progestin, there was an
enhanced PARP1 enzymatic activity (92). PARP1 activation
also led to a global increase in PAR levels, essential for the
modulation of the majority of progesterone-regulated
genes. Inhibition of PARP1 blocked the downstream
activation or repression of 85% of progestin target
genes. As a consequence, given the multiplicity of genes
affected, PARP1 could be a potential target for the pharma-
cological management of breast cancer. Along this line,This work is licensed under a Creative Commons
Attribution 3.0 Unported License.
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7–12 3 :R7new therapeutic approaches targeting breast cancer which
involve PARP1 have been proposed (93, 94).
As mentioned, PARP1 interacts and regulates multiple
NRs involved in endocrine maintenance. Interestingly,
the putative interaction of PARP1 with the GR has not
been explored yet. This interaction could be relevant in
the maintenance of neuroendocrine circuits as PARP1
could be modulating the effects of the GR (Fig. 1).
The review highlights that PARP1 is important in the
inflammatory response, hence the coregulation with
the GR might be relevant for their function.PARP1 in inflammation
As described previously for the GR, immune and
inflammatory responses are the best-characterized PARP1-
dependent biological responses (95). PARP1 is heavily
automodified upon bacterial infection (96) and Parp1K/K
mice have proven to be resistant to inflammation in
different experimental models, such as LPS-induced septic
shock and streptozotocin-induced diabetes (97, 98). Inter-
estingly, PARP-dependent proinflammatory responses
are not limited to cells of the immune system: PARP is
implicated in the pathological proinflammatory responses
to stress in cells of the CNS as well. In contrast to the well
characterized GR anti-inflammatory action, PARP1 acti-
vation in glial cells mediates the function of TFs that control
the expression of genes of the inflammatory response,
such as NF-kB and AP1. In models of cerebral ischemia,
expression of genes such as IL6, IL1B, COX2, iNOS, and
ICAM1 is elevated, while in PARP1 knockout mice or after
the administration of PARP inhibitors, expression of these
genes is significantly reduced (99, 100, 101, 102, 103).
These findings led to the notion that PARP1 is an
important mediator of inflammatory responses on cells
subjected to different stimuli. In this aspect, it was already
recognized almost two decades ago that PARP1 inhibitors
haveanti-inflammatoryproperties (104),being this a subject
of still intense research. A considerable number of TFs
known to be involved in the regulation of expression of
inflammatory mediators have been shown to interact with
PARP1. The first one to be identified was NF-kB (105, 106).
Upon PARP1 deletion, gene expression induced by NF-kB
was abolished, thus reducing proinflammatory cytokines
(TNFa and iNOS) expression after LPS injury (106). These
effects were also observed in the CNS. PARP1K/K glial cells
showed a diminished DNA-binding activity of NF-kB, with
the subsequent reduction in expression of proinflammatory
mediators includingIL6, IL1b, TNFa,COX2,and iNOS(100).
Afterwards, other TFs and cofactors that are involved in thehttp://www.endocrineconnections.org
DOI: 10.1530/EC-13-0079
 2014 The authors
Published by Bioscientifica Ltdregulation of inflammation were found to be modulated
by PARP1, such as AP1 (97, 107), NFAT (108, 109), SIRT1
(110), and Sp1 (100). The precise mechanism of regulation
of these TFs is still a matter of intense research, being
a common point the fact that PARP1 activity enhances
DNA-binding capacities of TFs. By regulating their
activity, PARP1 ultimately regulates the expression of
inflammatory cytokines such as TNFa, IL1b, IL6, and IL12,
which in turn activate the expression of other cytokines,
chemokines, iNOS, and COX2, suggesting that PARP1
plays an important role in several pathophysiological
inflammatory responses.
As described earlier, PARP1 regulates transcription in a
wide array of systems, including immune cells, endocrine
tumors, and glial cells. As such, PARP1 involvement in
neuronal and glial physiology is proving to be quite
important. The relevance of PARP1 in the CNS is receiving
considerable attention. PARP1 has been shown to be
involved in different injury mechanisms affecting
neurons. As previously described for GC-mediated apop-
tosis (30), it is already recognized that PARP1-mediated
cell death is one of the dominant cell death process in
many disease settings (111). PARP1 activation has been
detected in various neurodegenerative disorders (112),
with a role also identified for the GR in these pathologies
(113, 114). It has been shown that elevated PARP1
activation levels are sufficient for neuronal death (115)
and astrocyte death (116). In more chronic CNS disease,
such as experimental autoimmune encephalomyelitis
(EAE) model where there is an important inflammatory
component, PAR accumulation has been found not only
in astrocytes surrounding demyelinated EAE plaques but
also to a lesser extent in microglia, oligodendrocytes, and
neurons (117). Finally, autopsy samples from Alzheimer
patients showed PAR accumulation in cortical pyramidal
neurons and in astrocytes, suggesting PARP1 activation,
with no PAR accumulation in microglia (118). PARP1
activation drives neuronal death elicited by fragments of
peptide b-amiloid, implicating PARP1 in the pathogenesis
of Alzheimer’s disease (119). Astrocytic PARP activation
seems to be quite a common feature of chronic neuro-
degenerative disorders, suggesting a key role for PARP1 in
these inflammatory diseases.
Taking into account the data reviewed so far, both
PARP1 and GR share common pathways. To explore the
putative interaction between these two molecules, one
interesting pathway to explore would be their opposing
role in the transcription of proinflammatory cytokines, by
means of antagonically regulating TFs activity such as
NF-kB and AP1 (Fig. 2).This work is licensed under a Creative Commons
Attribution 3.0 Unported License.
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Interaction with TFs and recruitment
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Figure 2
GR and PARP1 in inflammation. GR and PARP1 regulate inflammatory
responses. GR inhibits the expression of inflammatory mediators through
the modulation of the transcriptional activity of inflammatory transcrip-
tion factors and expression of anti-inflammatory genes. On the contrary,
PARP1 induces the expression of inflammatory mediators through
stimulation of the transcriptional activity of inflammatory transcription
factors. The interplay between GR and PARP1 in the final outcome of
inflammatory responses remains to be elucidated.
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be involved in anti-inflammatory mechanisms driven by
the GR. Upon ligand binding and traslocation to the
nucleus, GR may reduce inflammatory effects mediated by
PARP1 on NF-kB. One feasible mechanism for this could be
that GR interaction with PARP1 reduces its activity on
NF-kB or that GR competes with PARP1 for NF-kB binding.
This last alternative is rather appealing, since it would
provide a fast fine-tuning for NF-kB-mediated transcrip-
tional regulation of inflammatory cytokines. Another
possibility is that PARP1 may be modulating GR activity
over NF-kB activation. This effect may be accomplished
by means of GR parylation or physical interaction
between these two molecules. These alternatives remain
to be explored.http://www.endocrineconnections.org
DOI: 10.1530/EC-13-0079
 2014 The authors
Published by Bioscientifica LtdConclusion
The neuroendocrine system has a determinant role in the
control of inflammatory mechanisms, in order to allow
the organism to return to homeostasis and therefore avoid
pathological situations of exacerbated inflammation. In
this context, both GR and PARP1 have prominent
antagonic roles in the regulation of inflammatory
processes. Although PARP1 and NRs have been reported
to functionally interact, there have not been reports so far
showing interaction between PARP and GR. It would be of
interest to address this issue, in order to confirm either a
direct or indirect interaction as it is the case between
PARP1 and other NRs, where PARP1 is a component of the
transcriptional complex that mediates steroid-drivenThis work is licensed under a Creative Commons
Attribution 3.0 Unported License.
E
n
d
o
cr
in
e
C
o
n
n
e
ct
io
n
s
Review F Aprile-Garcia et al. Neuroendocrine control of
inflammation
9–12 3 :R9transcription. Considering that PARP1 and GR do share
common targets involved in inflammatory responses, the
possibility that PARP1 may have a role in the regulation of
cytokine and other inflammatory mediators expression
mediated by GCs at the CNS level arises. In this context, it
would also be interesting to explore whether through the
mechanisms discussed above PARP1 may be playing a role
in mediating the well-known patient GC resistance in
inflammatory disease. The understanding of the molecular
mechanism leading to the antagonic effect of these two
regulators may provide novel targets in the neuroendo-
crine control of inflammation.Declaration of interest
The authors declare that there is no conflict of interest that could be
perceived as prejudicing the impartiality of the review.Funding
This work was supported by grants from the Max Planck Society, Germany;
the University of Buenos Aires; CONICET; the Agencia Nacional de
Promocio´n Cientı´fica y Tecnolo´gica, Argentina; and FOCEM-Mercosur
(COF 03/11).References
1 Medzhitov R. Origin and physiological roles of inflammation. Nature
2008 454 428–435. (doi:10.1038/nature07201)
2 Dinarello CA. Anti-inflammatory agents: present and future. Cell 2010
140 935–950. (doi:10.1016/j.cell.2010.02.043)
3 Chiu R, Boyle WJ, Meek J, Smeal T, Hunter T & Karin M. The c-Fos
protein interacts with c-Jun/AP-1 to stimulate transcription of AP-1
responsive genes. Cell 1988 54 541–552. (doi:10.1016/0092-8674
(88)90076-1)
4 Auphan N, DiDonato JA, Rosette C, Helmberg A & Karin M.
Immunosuppression by glucocorticoids: inhibition of NF-kB activity
through induction of IkB synthesis. Science 1995 270 286–290.
(doi:10.1126/science.270.5234.286)
5 Hayden MS & Ghosh S. Shared principles in NF-kB signaling. Cell 2008
132 344–362. (doi:10.1016/j.cell.2008.01.020)
6 Elenkov IJ, Iezzoni DG, Daly A, Harris AG & Chrousos GP. Cytokine
dysregulation, inflammation and well-being. Neuroimmunomodulation
2005 12 255–269. (doi:10.1159/000087104)
7 Ridker PM, Hennekens CH, Roitman-Johnson B, Stampfer MJ &
Allen J. Plasma concentration of soluble intercellular adhesion
molecule 1 and risks of future myocardial infarction in apparently
healthy men. Lancet 1998 351 88–92. (doi:10.1016/S0140-6736
(97)09032-6)
8 Rohleder N. Acute and chronic stress induced changes in
sensitivity of peripheral inflammatory pathways to the signals of
multiple stress systems – 2011 Curt Richter Award Winner.
Psychoneuroendocrinology 2012 37 307–316. (doi:10.1016/
j.psyneuen.2011.12.015)
9 Dantzer R, O’Connor JC, Freund GG, Johnson RW & Kelley KW.
From inflammation to sickness and depression: when the immune
system subjugates the brain. Nature Reviews. Neuroscience 2008 9 46–56.
(doi:10.1038/nrn2297)http://www.endocrineconnections.org
DOI: 10.1530/EC-13-0079
 2014 The authors
Published by Bioscientifica Ltd10 Besedovsky HO & del Rey A. Immune–neuroendocrine circuits:
integrative role of cytokines. Frontiers in Neuroendocrinology 1992 13
61–94.
11 De Kloet ER, Vreugdenhil E, Oitzl MS & Joels M. Brain corticosteroid
receptor balance in health and disease. Endocrine Reviews 1998 19
269–301. (doi:10.1210/er.19.3.269)
12 Smith SM & Vale WW. The role of the hypothalamic–pituitary–
adrenal axis in neuroendocrine responses to stress. Dialogues in Clinical
Neuroscience 2006 8 383–395.
13 Green PG, Miao FJ, Janig W & Levine JD. Negative feedback
neuroendocrine control of the inflammatory response in rats.
Journal of Neuroscience 1995 15 4678–4686.
14 McKay LI & Cidlowski JA. Molecular control of immune/inflammatory
responses: interactions between nuclear factor-kB and steroid
receptor-signaling pathways. Endocrine Reviews 1999 20 435–459.
(doi:10.1210/er.20.4.435)
15 Besedovsky H, del Rey A, Sorkin E & Dinarello CA. Immunoregulatory
feedback between interleukin-1 and glucocorticoid hormones. Science
1986 233 652–654. (doi:10.1126/science.3014662)
16 de Kloet ER, Joels M & Holsboer F. Stress and the brain: from
adaptation to disease. Nature Reviews. Neuroscience 2005 6 463–475.
(doi:10.1038/nrn1683)
17 Arzt E, Pereda MP, Castro CP, Pagotto U, Renner U & Stalla GK.
Pathophysiological role of the cytokine network in the anterior
pituitary gland. Frontiers in Neuroendocrinology 1999 20 71–95.
(doi:10.1006/frne.1998.0176)
18 Liberman AC, Druker J, Perone MJ & Arzt E. Glucocorticoids in the
regulation of transcription factors that control cytokine synthesis.
Cytokine & Growth Factor Reviews 2007 18 45–56. (doi:10.1016/
j.cytogfr.2007.01.005)
19 Sapolsky RM, Romero LM & Munck AU. How do glucocorticoids
influence stress responses? Integrating permissive, suppressive,
stimulatory, and preparative actions Endocrine Reviews 2000 21 55–89.
(doi:10.1210/er.21.1.55)
20 Cooper MS, Bujalska I, Rabbitt E, Walker EA, Bland R, Sheppard MC,
Hewison M & Stewart PM. Modulation of 11b-hydroxysteroid
dehydrogenase isozymes by proinflammatory cytokines in osteo-
blasts: an autocrine switch from glucocorticoid inactivation to
activation. Journal of Bone and Mineral Research 2001 16 1037–1044.
(doi:10.1359/jbmr.2001.16.6.1037)
21 Hardy RS, Filer A, Cooper MS, Parsonage G, Raza K, Hardie DL,
Rabbitt EH, Stewart PM, Buckley CD & Hewison M. Differential
expression, function and response to inflammatory stimuli of
11b-hydroxysteroid dehydrogenase type 1 in human fibroblasts:
a mechanism for tissue-specific regulation of inflammation. Arthritis
Research & Therapy 2006 8 R108. (doi:10.1186/ar1993)
22 Kaur K, Hardy R, Ahasan MM, Eijken M, van Leeuwen JP, Filer A,
Thomas AM, Raza K, Buckley CD, Stewart PM et al. Synergistic
induction of local glucocorticoid generation by inflammatory
cytokines and glucocorticoids: implications for inflammation
associated bone loss. Annals of the Rheumatic Diseases 2010 69
1185–1190. (doi:10.1136/ard.2009.107466)
23 Ahasan MM, Hardy R, Jones C, Kaur K, Nanus D, Juarez M, Morgan SA,
Hassan-Smith Z, Benezech C, Caamano JH et al. Inflammatory
regulation of glucocorticoid metabolism in mesenchymal stromal
cells. Arthritis and Rheumatism 2012 64 2404–2413. (doi:10.1002/
art.34414)
24 Raza K, Hardy R & Cooper MS. The 11b-hydroxysteroid dehydrogenase
enzymes – arbiters of the effects of glucocorticoids in synovium and
bone. Rheumatology 2010 49 2016–2023. (doi:10.1093/rheumatology/
keq212)
25 Beck IM, Vanden Berghe W, Vermeulen L, Yamamoto KR,
Haegeman G & De Bosscher K. Crosstalk in inflammation: the
interplay of glucocorticoid receptor-based mechanisms and kinases
and phosphatases. Endocrine Reviews 2009 30 830–882. (doi:10.1210/
er.2009-0013)This work is licensed under a Creative Commons
Attribution 3.0 Unported License.
E
n
d
o
cr
in
e
C
o
n
n
e
ct
io
n
s
Review F Aprile-Garcia et al. Neuroendocrine control of
inflammation
10–12 3 :R1026 Schaaf MJ, Lewis-Tuffin LJ & Cidlowski JA. Ligand-selective targeting
of the glucocorticoid receptor to nuclear subdomains is associated
with decreased receptor mobility. Molecular Endocrinology 2005 19
1501–1515. (doi:10.1210/me.2005-0050)
27 Vandevyver S, Dejager L & Libert C. On the trail of the glucocorticoid
receptor: into the nucleus and back. Traffic 2012 13 364–374.
(doi:10.1111/j.1600-0854.2011.01288.x)
28 Clark AR. Anti-inflammatory functions of glucocorticoid-induced
genes. Molecular and Cellular Endocrinology 2007 275 79–97.
(doi:10.1016/j.mce.2007.04.013)
29 De Bosscher K, Vanden Berghe W & Haegeman G. The interplay
between the glucocorticoid receptor and nuclear factor-kB or activator
protein-1: molecular mechanisms for gene repression. Endocrine
Reviews 2003 24 488–522. (doi:10.1210/er.2002-0006)
30 Rhen T & Cidlowski JA. Antiinflammatory action of glucocorticoids –
new mechanisms for old drugs. New England Journal of Medicine 2005
353 1711–1723. (doi:10.1056/NEJMra050541)
31 Scheinman RI, Gualberto A, Jewell CM, Cidlowski JA & Baldwin AS Jr.
Characterization of mechanisms involved in transrepression of NF-kB
by activated glucocorticoid receptors. Molecular and Cellular Biology
1995 15 943–953.
32 Kassel O & Herrlich P. Crosstalk between the glucocorticoid receptor
and other transcription factors: molecular aspects. Molecular and
Cellular Endocrinology 2007 275 13–29. (doi:10.1016/j.mce.2007.
07.003)
33 Pascual G & Glass CK. Nuclear receptors versus inflammation:
mechanisms of transrepression. Trends in Endocrinology and Metabolism
2006 17 321–327. (doi:10.1016/j.tem.2006.08.005)
34 De Bosscher K, Vanden Berghe W & Haegeman G. Cross-talk between
nuclear receptors and nuclear factor kB. Oncogene 2006 25 6868–6886.
(doi:10.1038/sj.onc.1209935)
35 Jonat C, Rahmsdorf HJ, Park KK, Cato AC, Gebel S, Ponta H &
Herrlich P. Antitumor promotion and antiinflammation: down-
modulation of AP-1 (Fos/Jun) activity by glucocorticoid hormone. Cell
1990 62 1189–1204. (doi:10.1016/0092-8674(90)90395-U)
36 Helmberg A, Auphan N, Caelles C & Karin M. Glucocorticoid-induced
apoptosis of human leukemic cells is caused by the repressive function
of the glucocorticoid receptor. EMBO Journal 1995 14 452–460.
37 Kovalovsky D, Refojo D, Holsboer F & Arzt E. Molecular mechanisms
and Th1/Th2 pathways in corticosteroid regulation of cytokine
production. Journal of Neuroimmunology 2000 109 23–29.
(doi:10.1016/S0165-5728(00)00298-8)
38 Vacca A, Felli MP, Farina AR, Martinotti S, Maroder M, Screpanti I,
Meco D, Petrangeli E, Frati L & Gulino A. Glucocorticoid receptor-
mediated suppression of the interleukin 2 gene expression through
impairment of the cooperativity between nuclear factor of activated
T cells and AP-1 enhancer elements. Journal of Experimental Medicine
1992 175 637–646. (doi:10.1084/jem.175.3.637)
39 De Bosscher K, Schmitz ML, Vanden Berghe W, Plaisance S, Fiers W &
Haegeman G. Glucocorticoid-mediated repression of nuclear
factor-kB-dependent transcription involves direct interference
with transactivation. PNAS 1997 94 13504–13509. (doi:10.1073/
pnas.94.25.13504)
40 De Bosscher K & Haegeman G. Minireview: latest perspectives on
antiinflammatory actions of glucocorticoids. Molecular Endocrinology
2009 23 281–291. (doi:10.1210/me.2008-0283)
41 Liberman AC, Druker J, Refojo D, Holsboer F & Arzt E. Glucocorticoids
inhibit GATA-3 phosphorylation and activity in T cells. FASEB Journal
2009 23 1558–1571. (doi:10.1096/fj.08-121236)
42 Liberman AC, Refojo D, Druker J, Toscano M, Rein T, Holsboer F &
Arzt E. The activated glucocorticoid receptor inhibits the transcription
factor T-bet by direct protein–protein interaction. FASEB Journal 2007
21 1177–1188. (doi:10.1096/fj.06-7452com)
43 Besedovsky HO & del Rey A. Regulating inflammation by glucocorti-
coids. Nature Immunology 2006 7 537. (doi:10.1038/ni0606-537)http://www.endocrineconnections.org
DOI: 10.1530/EC-13-0079
 2014 The authors
Published by Bioscientifica Ltd44 Liberman AC, Castro CN, Antunica Noguerol M, Barcala
Tabarrozzi AE, Druker J, Perone MJ & Arzt E. Molecular mechanisms of
glucocorticoids action: from basic research to clinical implications.
Current Immunology Reviews 2010 6 371–380. (doi:10.2174/
1573395511006040371)
45 De Bosscher K, Beck IM & Haegeman G. Classic glucocorticoids versus
non-steroidal glucocorticoid receptor modulators: survival of the
fittest regulator of the immune system? Brain, Behavior, and Immunity
2010 24 1035–1042. (doi:10.1016/j.bbi.2010.06.010)
46 De Bosscher K, Haegeman G & Elewaut D. Targeting inflammation
using selective glucocorticoid receptor modulators. Current Opinion in
Pharmacology 2010 10 497–504. (doi:10.1016/j.coph.2010.04.007)
47 De Bosscher K, Van Craenenbroeck K, Meijer OC & Haegeman G.
Selective transrepression versus transactivation mechanisms by
glucocorticoid receptor modulators in stress and immune systems.
European Journal of Pharmacology 2008 583 290–302. (doi:10.1016/
j.ejphar.2007.11.076)
48 Belvisi MG, Wicks SL, Battram CH, Bottoms SE, Redford JE,
Woodman P, Brown TJ, Webber SE & Foster ML. Therapeutic benefit of
a dissociated glucocorticoid and the relevance of in vitro separation of
transrepression from transactivation activity. Journal of Immunology
2001 166 1975–1982.
49 Vayssiere BM, Dupont S, Choquart A, Petit F, Garcia T,
Marchandeau C, Gronemeyer H & Resche-Rigon M. Synthetic
glucocorticoids that dissociate transactivation and AP-1 transrepres-
sion exhibit antiinflammatory activity in vivo. Molecular Endocrinology
1997 11 1245–1255. (doi:10.1210/me.11.9.1245)
50 De Bosscher K, Vanden Berghe W, Beck IM, Van Molle W,
Hennuyer N, Hapgood J, Libert C, Staels B, Louw A & Haegeman G.
A fully dissociated compound of plant origin for inflammatory gene
repression. PNAS 2005 102 15827–15832. (doi:10.1073/pnas.
0505554102)
51 De Bosscher K, Beck IM, Dejager L, Bougarne N, Gaigneaux A,
Chateauvieux S, Ratman D, Bracke M, Tavernier J, Vanden Berghe W
et al. Selective modulation of the glucocorticoid receptor can distinguish
between transrepression of NF-kB and AP-1. Cellular and Molecular Life
Sciences 2013 [in press]. (doi:10.1007/s00018-013-1367-4)
52 So AY, Chaivorapol C, Bolton EC, Li H & Yamamoto KR. Determinants
of cell- and gene-specific transcriptional regulation by the glucocor-
ticoid receptor. PLoS Genetics 2007 3 e94. (doi:10.1371/journal.pgen.
0030094)
53 Barnes PJ. Glucocorticosteroids: current and future directions. British
Journal of Pharmacology 2011 163 29–43. (doi:10.1111/j.1476-5381.
2010.01199.x)
54 Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G,
Umesono K, Blumberg B, Kastner P, Mark M, Chambon P et al.
The nuclear receptor superfamily: the second decade. Cell 1995 83
835–839. (doi:10.1016/0092-8674(95)90199-X)
55 Dijsselbloem N, Vanden Berghe W, De Naeyer A & Haegeman G.
Soy isoflavone phyto-pharmaceuticals in interleukin-6 affections.
Multi-purpose nutraceuticals at the crossroad of hormone
replacement, anti-cancer and anti-inflammatory therapy.
Biochemical Pharmacology 2004 68 1171–1185. (doi:10.1016/
j.bcp.2004.05.036)
56 Cinar B, De Benedetti A & Freeman MR. Post-transcriptional
regulation of the androgen receptor by mammalian target of
rapamycin. Cancer Research 2005 65 2547–2553. (doi:10.1158/
0008-5472.CAN-04-3411)
57 Mauro C, Zazzeroni F, Papa S, Bubici C & Franzoso G. The NF-kB
transcription factor pathway as a therapeutic target in cancer:
methods for detection of NF-kB activity. Methods in Molecular Biology
2009 512 169–207. (doi:10.1007/978-1-60327-530-9_10)
58 Gonzalez-Angulo AM, Morales-Vasquez F & Hortobagyi GN.
Overview of resistance to systemic therapy in patients with breast
cancer. Advances in Experimental Medicine and Biology 2007 608 1–22.
(doi:10.1007/978-0-387-74039-3_1)This work is licensed under a Creative Commons
Attribution 3.0 Unported License.
E
n
d
o
cr
in
e
C
o
n
n
e
ct
io
n
s
Review F Aprile-Garcia et al. Neuroendocrine control of
inflammation
11–12 3 :R1159 Hermanson O, Glass CK & Rosenfeld MG. Nuclear receptor coregu-
lators: multiple modes of modification. Trends in Endocrinology and
Metabolism 2002 13 55–60. (doi:10.1016/S1043-2760(01)00527-6)
60 Kim MY, Woo EM, Chong YT, Homenko DR & Kraus WL. Acetylation
of estrogen receptor a by p300 at lysines 266 and 268 enhances the
deoxyribonucleic acid binding and transactivation activities of the
receptor. Molecular Endocrinology 2006 20 1479–1493. (doi:10.1210/
me.2005-0531)
61 Perkins ND. Post-translational modifications regulating the activity
and function of the nuclear factor kB pathway. Oncogene 2006 25
6717–6730. (doi:10.1038/sj.onc.1209937)
62 Ito K, Yamamura S, Essilfie-Quaye S, Cosio B, Ito M, Barnes PJ &
Adcock IM. Histone deacetylase 2-mediated deacetylation of the
glucocorticoid receptor enables NF-kB suppression. Journal of
Experimental Medicine 2006 203 7–13. (doi:10.1084/jem.20050466)
63 Ame JC, Spenlehauer C & de Murcia G. The PARP superfamily.
BioEssays 2004 26 882–893. (doi:10.1002/bies.20085)
64 Otto H, Reche PA, Bazan F, Dittmar K, Haag F & Koch-Nolte F. In silico
characterization of the family of PARP-like poly(ADP-ribosyl)trans-
ferases (pARTs). BMC Genomics 2005 6 139. (doi:10.1186/1471-2164-
6-139)
65 D’Amours D, Desnoyers S, D’Silva I & Poirier GG. Poly(ADP-
ribosyl)ation reactions in the regulation of nuclear functions.
Biochemical Journal 1999 342 249–268. (doi:10.1042/0264-
6021:3420249)
66 Zhang Y, Wang J, Ding M & Yu Y. Site-specific characterization of
the Asp- and Glu-ADP-ribosylated proteome. Nature Methods 2013 10
981–984. (doi:10.1038/nmeth.2603)
67 Altmeyer M, Messner S, Hassa PO, Fey M & Hottiger MO. Molecular
mechanism of poly(ADP-ribosyl)ation by PARP1 and identification of
lysine residues as ADP-ribose acceptor sites. Nucleic Acids Research 2009
37 3723–3738. (doi:10.1093/nar/gkp229)
68 Hassa PO & Hottiger MO. The diverse biological roles of mammalian
PARPS, a small but powerful family of poly-ADP-ribose polymerases.
Frontiers in Bioscience 2008 13 3046–3082. (doi:10.2741/2909)
69 Benjamin RC & Gill DM. Poly(ADP-ribose) synthesis in vitro pro-
grammed by damaged DNA. A comparison of DNA molecules
containing different types of strand breaks. Journal of Biological
Chemistry 1980 255 10502–10508.
70 Kraus WL & Hottiger MO. PARP-1 and gene regulation: progress
and puzzles. Molecular Aspects of Medicine 2013 34 1109–1123.
(doi:10.1016/j.mam.2013.01.005)
71 Kraus WL & Lis JT. PARP goes transcription. Cell 2003 113 677–683.
(doi:10.1016/S0092-8674(03)00433-1)
72 Mendoza-Alvarez H & Alvarez-Gonzalez R. Regulation of p53
sequence-specific DNA-binding by covalent poly(ADP-ribosyl)ation.
Journal of Biological Chemistry 2001 276 36425–36430. (doi:10.1074/
jbc.M105215200)
73 Kraus WL. Transcriptional control by PARP-1: chromatin modulation,
enhancer-binding, coregulation, and insulation. Current Opinion in
Cell Biology 2008 20 294–302. (doi:10.1016/j.ceb.2008.03.006)
74 Ji Y & Tulin AV. The roles of PARP1 in gene control and cell
differentiation. Current Opinion in Genetics & Development 2010 20
512–518. (doi:10.1016/j.gde.2010.06.001)
75 Krishnakumar R & Kraus WL. The PARP side of the nucleus: molecular
actions, physiological outcomes, and clinical targets. Molecular Cell
2010 39 8–24. (doi:10.1016/j.molcel.2010.06.017)
76 Huletsky A, de Murcia G, Muller S, Hengartner M, Menard L,
Lamarre D & Poirier GG. The effect of poly(ADP-ribosyl)ation on
native and H1-depleted chromatin. A role of poly(ADP-ribosyl)ation
on core nucleosome structure. Journal of Biological Chemistry 1989 264
8878–8886.
77 Poirier GG, de Murcia G, Jongstra-Bilen J, Niedergang C & Mandel P.
Poly(ADP-ribosyl)ation of polynucleosomes causes relaxation of
chromatin structure. PNAS 1982 79 3423–3427. (doi:10.1073/pnas.79.
11.3423)http://www.endocrineconnections.org
DOI: 10.1530/EC-13-0079
 2014 The authors
Published by Bioscientifica Ltd78 Kim MY, Mauro S, Gevry N, Lis JT & Kraus WL. NADC-dependent
modulation of chromatin structure and transcription by nucleosome
binding properties of PARP-1. Cell 2004 119 803–814. (doi:10.1016/
j.cell.2004.11.002)
79 Wacker DA, Ruhl DD, Balagamwala EH, Hope KM, Zhang T &
Kraus WL. The DNA binding and catalytic domains of poly(ADP-
ribose) polymerase 1 cooperate in the regulation of chromatin
structure and transcription. Molecular and Cellular Biology 2007 27
7475–7485. (doi:10.1128/MCB.01314-07)
80 Krishnakumar R, Gamble MJ, Frizzell KM, Berrocal JG, Kininis M &
Kraus WL. Reciprocal binding of PARP-1 and histone H1 at promoters
specifies transcriptional outcomes. Science 2008 319 819–821.
(doi:10.1126/science.1149250)
81 Ju BG, Lunyak VV, Perissi V, Garcia-Bassets I, Rose DW, Glass CK &
Rosenfeld MG. A topoisomerase IIb-mediated dsDNA break required
for regulated transcription. Science 2006 312 1798–1802. (doi:10.1126/
science.1127196)
82 Slattery E, Dignam JD, Matsui T & Roeder RG. Purification and analysis
of a factor which suppresses nick-induced transcription by RNA
polymerase II and its identity with poly(ADP-ribose) polymerase.
Journal of Biological Chemistry 1983 258 5955–5959.
83 Hassa PO, Buerki C, Lombardi C, Imhof R & Hottiger MO.
Transcriptional coactivation of nuclear factor-kB-dependent gene
expression by p300 is regulated by poly(ADP)-ribose polymerase-1.
Journal of Biological Chemistry 2003 278 45145–45153. (doi:10.1074/
jbc.M307957200)
84 Hassa PO, Haenni SS, Buerki C, Meier NI, Lane WS, Owen H,
Gersbach M, Imhof R & Hottiger MO. Acetylation of poly(ADP-ribose)
polymerase-1 by p300/CREB-binding protein regulates coactivation of
NF-kB-dependent transcription. Journal of Biological Chemistry 2005
280 40450–40464. (doi:10.1074/jbc.M507553200)
85 Pavri R, Lewis B, Kim TK, Dilworth FJ, Erdjument-Bromage H,
Tempst P, de Murcia G, Evans R, Chambon P & Reinberg D. PARP-1
determines specificity in a retinoid signaling pathway via direct
modulation of mediator. Molecular Cell 2005 18 83–96. (doi:10.1016/
j.molcel.2005.02.034)
86 Attwood JT, Yung RL & Richardson BC. DNA methylation and the
regulation of gene transcription. Cellular and Molecular Life Sciences
2002 59 241–257. (doi:10.1007/s00018-002-8420-z)
87 Caiafa P & Zampieri M. DNA methylation and chromatin structure:
the puzzling CpG islands. Journal of Cellular Biochemistry 2005 94
257–265. (doi:10.1002/jcb.20325)
88 Caiafa P, Guastafierro T & Zampieri M. Epigenetics: poly(ADP-
ribosyl)ation of PARP-1 regulates genomic methylation patterns.
FASEB Journal 2009 23 672–678. (doi:10.1096/fj.08-123265)
89 Reale A, Matteis GD, Galleazzi G, Zampieri M & Caiafa P. Modulation
of DNMT1 activity by ADP-ribose polymers. Oncogene 2005 24 13–19.
(doi:10.1038/sj.onc.1208005)
90 Schiewer MJ, Goodwin JF, Han S, Brenner JC, Augello MA, Dean JL,
Liu F, Planck JL, Ravindranathan P, Chinnaiyan AM et al. Dual roles of
PARP-1 promote cancer growth and progression. Cancer Discovery 2012
2 1134–1149. (doi:10.1158/2159-8290.CD-12-0120)
91 Sartorius CA, Takimoto GS, Richer JK, Tung L & Horwitz KB.
Association of the Ku autoantigen/DNA-dependent protein kinase
holoenzyme and poly(ADP-ribose) polymerase with the DNA binding
domain of progesterone receptors. Journal of Molecular Endocrinology
2000 24 165–182. (doi:10.1677/jme.0.0240165)
92 Wright RH, Castellano G, Bonet J, Le Dily F, Font-Mateu J, Ballare C,
Nacht AS, Soronellas D, Oliva B & Beato M. CDK2-dependent
activation of PARP-1 is required for hormonal gene regulation in
breast cancer cells. Genes and Development 2012 26 1972–1983.
(doi:10.1101/gad.193193.112)
93 Inbar-Rozensal D, Castiel A, Visochek L, Castel D, Dantzer F, Izraeli S &
Cohen-Armon M. A selective eradication of human nonhereditary
breast cancer cells by phenanthridine-derived polyADP-riboseThis work is licensed under a Creative Commons
Attribution 3.0 Unported License.
E
n
d
o
cr
in
e
C
o
n
n
e
ct
io
n
s
Review F Aprile-Garcia et al. Neuroendocrine control of
inflammation
12–12 3 :R12polymerase inhibitors. Breast Cancer Research 2009 11 R78.
(doi:10.1186/bcr2445)
94 Rehman FL, Lord CJ & Ashworth A. The promise of combining
inhibition of PI3K and PARP as cancer therapy. Cancer Discovery 2012 2
982–984. (doi:10.1158/2159-8290.CD-12-0433)
95 Cuzzocrea S. Shock, inflammation and PARP. Pharmacological Research
2005 52 72–82. (doi:10.1016/j.phrs.2005.02.016)
96 Nossa CW, Jain P, Tamilselvam B, Gupta VR, Chen LF, Schreiber V,
Desnoyers S & Blanke SR. Activation of the abundant nuclear factor
poly(ADP-ribose) polymerase-1 by Helicobacter pylori. PNAS 2009 106
19998–20003. (doi:10.1073/pnas.0906753106)
97 Ha HC. Defective transcription factor activation for proinflammatory
gene expression in poly(ADP-ribose) polymerase 1-deficient glia. PNAS
2004 101 5087–5092. (doi:10.1073/pnas.0306895101)
98 Mabley JG, Suarez-Pinzon WL, Hasko G, Salzman AL, Rabinovitch A,
Kun E & Szabo C. Inhibition of poly (ADP-ribose) synthetase by gene
disruption or inhibition with 5-iodo-6-amino-1,2-benzopyrone pro-
tects mice from multiple-low-dose-streptozotocin-induced diabetes.
British Journal of Pharmacology 2001 133 909–919. (doi:10.1038/sj.bjp.
0704156)
99 Chiarugi A & Moskowitz MA. Poly(ADP-ribose) polymerase-1 activity
promotes NF-kB-driven transcription and microglial activation:
implication for neurodegenerative disorders. Journal of Neurochemistry
2003 85 306–317. (doi:10.1046/j.1471-4159.2003.01684.x)
100 Ha HC, Hester LD & Snyder SH. Poly(ADP-ribose) polymerase-1
dependence of stress-induced transcription factors and associated
gene expression in glia. PNAS 2002 99 3270–3275. (doi:10.1073/pnas.
052712399)
101 Lee JH, Park SY, Shin HK, Kim CD, Lee WS & Hong KW. Poly(ADP-
ribose) polymerase inhibition by cilostazol is implicated in the
neuroprotective effect against focal cerebral ischemic infarct in rat.
Brain Research 2007 1152 182–190. (doi:10.1016/j.brainres.2007.
03.035)
102 Moroni F. Poly(ADP-ribose)polymerase 1 (PARP-1) and postischemic
brain damage. Current Opinion in Pharmacology 2008 8 96–103.
(doi:10.1016/j.coph.2007.10.005)
103 Nakajima H, Nagaso H, Kakui N, Ishikawa M, Hiranuma T &
Hoshiko S. Critical role of the automodification of poly(ADP-ribose)
polymerase-1 in nuclear factor-kB-dependent gene expression in
primary cultured mouse glial cells. Journal of Biological Chemistry 2004
279 42774–42786. (doi:10.1074/jbc.M407923200)
104 Weltin D, Picard V, Aupeix K, Varin M, Oth D, Marchal J, Dufour P &
Bischoff P. Immunosuppressive activities of 6(5H)-phenanthridinone,
a new poly(ADP-ribose)polymerase inhibitor. International Journal of
Immunopharmacology 1995 17 265–271. (doi:10.1016/0192-0561
(95)00007-O)
105 Hassa PO & Hottiger MO. A role of poly (ADP-ribose) polymerase
in NF-kB transcriptional activation. Biological Chemistry 1999 380
953–959. (doi:10.1515/BC.1999.118)
106 Oliver FJ, Menissier-de Murcia J, Nacci C, Decker P,
Andriantsitohaina R, Muller S, de la Rubia G, Stoclet JC & de Murcia G.
Resistance to endotoxic shock as a consequence of defective NF-kB
activation in poly (ADP-ribose) polymerase-1 deficient mice. EMBO
Journal 1999 18 4446–4454. (doi:10.1093/emboj/18.16.4446)http://www.endocrineconnections.org
DOI: 10.1530/EC-13-0079
 2014 The authors
Published by Bioscientifica Ltd107 Zingarelli B, Hake PW, Burroughs TJ, Piraino G, O’Connor M &
Denenberg A. Activator protein-1 signalling pathway and apoptosis
are modulated by poly(ADP-ribose) polymerase-1 in experimental
colitis. Immunology 2004 113 509–517. (doi:10.1111/j.1365-2567.
2004.01991.x)
108 Olabisi OA, Soto-Nieves N, Nieves E, Yang TT, Yang X, Yu RY, Suk HY,
Macian F & Chow CW. Regulation of transcription factor NFAT by
ADP-ribosylation. Molecular and Cellular Biology 2008 28 2860–2871.
(doi:10.1128/MCB.01746-07)
109 Valdor R, Schreiber V, Saenz L, Martinez T, Munoz-Suano A,
Dominguez-Villar M, Ramirez P, Parrilla P, Aguado E, Garcia-Cozar F
et al. Regulation of NFAT by poly(ADP-ribose) polymerase activity
in T cells. Molecular Immunology 2008 45 1863–1871. (doi:10.1016/
j.molimm.2007.10.044)
110 Bai P, Canto C, Oudart H, Brunyanszki A, Cen Y, Thomas C,
Yamamoto H, Huber A, Kiss B, Houtkooper RH et al. PARP-1 inhibition
increases mitochondrial metabolism through SIRT1 activation.
Cell Metabolism 2011 13 461–468. (doi:10.1016/j.cmet.2011.03.004)
111 Kauppinen TM & Swanson RA. The role of poly(ADP-ribose)
polymerase-1 in CNS disease. Neuroscience 2007 145 1267–1272.
(doi:10.1016/j.neuroscience.2006.09.034)
112 Eliasson MJ, Sampei K, Mandir AS, Hurn PD, Traystman RJ, Bao J,
Pieper A, Wang ZQ, Dawson TM, Snyder SH et al. Poly(ADP-ribose)
polymerase gene disruption renders mice resistant to cerebral
ischemia. Nature Medicine 1997 3 1089–1095. (doi:10.1038/
nm1097-1089)
113 Ros-Bernal F, Hunot S, Herrero MT, Parnadeau S, Corvol JC, Lu L,
Alvarez-Fischer D, Carrillo-de Sauvage MA, Saurini F, Coussieu C et al.
Microglial glucocorticoid receptors play a pivotal role in regulating
dopaminergic neurodegeneration in parkinsonism. PNAS 2011 108
6632–6637. (doi:10.1073/pnas.1017820108)
114 Bhatt AJ, Feng Y, Wang J, Famuyide M & Hersey K. Dexamethasone
induces apoptosis of progenitor cells in the subventricular zone and
dentate gyrus of developing rat brain. Journal of Neuroscience Research
2013 91 1191–1202. (doi:10.1002/jnr.23232)
115 Alano CC, Garnier P, Ying W, Higashi Y, Kauppinen TM &
Swanson RA. NADC depletion is necessary and sufficient for
poly(ADP-ribose) polymerase-1-mediated neuronal death. Journal of
Neuroscience 2010 30 2967–2978. (doi:10.1523/JNEUROSCI.5552-09.
2010)
116 Tang KS, Suh SW, Alano CC, Shao Z, Hunt WT, Swanson RA &
Anderson CM. Astrocytic poly(ADP-ribose) polymerase-1 activation
leads to bioenergetic depletion and inhibition of glutamate uptake
capacity. Glia 2010 58 446–457. (doi:10.1002/glia.20936)
117 Scott GS, Hake P, Kean RB, Virag L, Szabo C & Hooper DC. Role of
poly(ADP-ribose) synthetase activation in the development of
experimental allergic encephalomyelitis. Journal of Neuroimmunology
2001 117 78–86. (doi:10.1016/S0165-5728(01)00329-0)
118 Love S, Barber R & Wilcock GK. Increased poly(ADP-ribosyl)ation of
nuclear proteins in Alzheimer’s disease. Brain 1999 122 247–253.
(doi:10.1093/brain/122.2.247)
119 Abeti R, Abramov AY & Duchen MR. b-Amyloid activates PARP
causing astrocytic metabolic failure and neuronal death. Brain 2011
134 1658–1672. (doi:10.1093/brain/awr104)Received in final form 13 November 2013
Accepted 15 November 2013This work is licensed under a Creative Commons
Attribution 3.0 Unported License.
